下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESR-18292Cat. No.: HY-101491CAS No.: 2095432-55-4分式: CHNO分量: 366.5作靶點: PGC-1作通路: Metabolic Enzyme/Protease儲存式: -80C, stored under nitrogen* 該產(chǎn)品在溶液狀態(tài)不穩(wěn)定,建議您現(xiàn)現(xiàn)配,即刻使。溶解性數(shù)據(jù)體外實驗 DMSO : 100 mg/mL (272.85 mM)* means soluble, but saturat
2、ion unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.7285 mL 13.6426 mL 27.2851 mL5 mM 0.5457 mL 2.7285 mL 5.4570 mL10 mM 0.2729 mL 1.3643 mL 2.7285 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液;該產(chǎn)品在溶液狀態(tài)不穩(wěn)定,建議您現(xiàn)現(xiàn)配,即刻使。體內(nèi)實驗 請根據(jù)您的實驗動物和給藥式選擇適當(dāng)?shù)娜芙獍?,配制前請先配制澄清的儲備液,再依次添加助溶?為保證實驗結(jié)果的可靠性,體內(nèi)實驗的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲
3、備液可以根據(jù)儲存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.82 mM); Clear solution2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (6.82 mM); Clear solution3. 請依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (
4、6.82 mM); Clear solution1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 SR-18292種 PPAR 共激活因-1 (PGC-1) 抑制劑,可促進(jìn) PGC-1 ?;?,抑制糖異基因的表達(dá),并減少肝細(xì)胞中葡萄糖的產(chǎn)。IC50 & Target PGC-1 1體外研究 The transcriptional coactivator PGC-1 plays a pivotal role in energy homeostasis by co-activatingtranscripti
5、on factors that regulate fat and glucose metabolism. SR-18292 increases the interaction of PGC-1with the acetyl transferase GCN5 and reduces co-activation of nuclear hormone receptor HNF4 by PGC-1.SR-18292 suppresses HNF4/PGC-1 gluconeogenic transcriptional function. By increasing the interactionof
6、GCN5 with PGC-1, SR-18292 increases the acetylation of specific PGC-1 lysine residues that mightsubsequently decrease its gluconeogenic activity 1.體內(nèi)研究 SR-18292 reduces fasting blood glucose, increases hepatic insulin sensitivity and improves glucosehomeostasis in diabetic mice. The high fat diet (H
7、FD) fed mice, a dietary model of obesity and T2D, aretreated with SR-18292 (45mg/kg) via I.P. injection for 3 consecutive days and again on day 4 beforemeasuring fasting blood glucose. Strikingly, mice that are treated with SR-18292 have significantly lowerlevels of fasting blood glucose concentrati
8、ons compared to matched vehicle-treated control mice. Theinduction of gluconeogenic gene expression is a regulatory component of the response to fasting.Importantly, gluconeogenic gene expression, specifically that of Pck1, is inhibited in livers isolated from micetreated with SR-18292 1.PROTOCOLKin
9、ase Assay 1 For determination of GCN5 HAT activity U-2 OS cells overexpressing Ad-GCN5 are treated with SR-18292(10 M) for 18 h. Cells are lysed with buffer B (20 mM HEPES-KOH (pH 7.9), 125 mM NaCl, 1 mM EDTA, 1mM DTT, 1% IGEPAL (v/v), 10% glycerol (v/v), 5 mM NaF, 5 mM -glycerophosphate, 5 mM sodiu
10、m butyrateand 10 mM nicotinamide), supplemented with Protease Inhibitor Cocktail. FLAG-GCN5 isimmunoprecipitated with FLAG beads overnight at 4C following multiple washes with lysis buffer. GCN5 isthen eluted using 3 FLAG peptide and the purified protein is used to determine HAT activity using the H
11、ATInhibitor Screening Assay Kit 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 1 For cell viability determination using MTT, primary hepatocytes are seeded on a 96-well plate at 20,000cells/well. The following day cells are treated at diff
12、erent doses, as indicated, for 18 h treatment of primaryhepatocytes. 5 L of MTT reagent (5 mg/mL) is then added to each well (n=4/dose) and cells are incubatedfor 1h at 37C. Medium is discarded and dye is extracted by adding 100 L DMSO to each well. Forcytotoxicity determination using ToxiLight Non-
13、destructive Cytotoxicity Bioassay, hepatocytes are seeded ona 6-well plate and treated with either SR-18292 (20 M) or Cisplatin (50 M) for 18 h. 50 L of medium iscollected and used to measure cellular toxicity by adding 100 of adenylate kinase detection reagent andincubating 5 min at RT before measu
14、ring luminescence 1.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEMCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 1Administration 1 For in vivo studies with DIO mice, males 6-8 weeks old are fed high fat diet (HFD) for the indicated time.
15、 Fordrug administration, SR-18292 (45 mg/kg) is injected via I.P. for 3 days between 4-5 pm and food is removedon day 3 at 5pm. The following morning (day 4) SR-18292 is injected again (for a total of 4 injections) andblood glucose is measured after 3 hours. Injection volume does not exceed 275 L pe
16、r mouse 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Cell Mol Neurobiol. 2019 Mar;39(2):265-286.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Sharabi K, et al. Selective Chemical Inhibition of PGC-1 Gluconeogenic Activity Ameliorates Type 2 Diab
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 落實學(xué)生返校教職工先行制度
- 用電安全培訓(xùn)課件大全
- 2026廣東廣州市花都區(qū)花東鎮(zhèn)大塘小學(xué)語文專任教師招聘1人備考考試試題附答案解析
- 2026年中國航天科技集團(tuán)有限公司第五研究院第五一0所校園招聘參考考試題庫附答案解析
- 2026年常德煙草機械有限責(zé)任公司招聘(35人)備考考試試題附答案解析
- 2026湖南婁底市婁星區(qū)青年就業(yè)見習(xí)單位第二批招募見習(xí)人員22人備考考試試題附答案解析
- 2026河南平頂山市宜陽縣第一批城鎮(zhèn)公益性崗位招聘100人備考考試題庫附答案解析
- 2026西藏山南市加查縣文旅局公益性崗位1人備考考試試題附答案解析
- 2026北京語言大學(xué)新編長聘人員招聘25人(第一批)備考考試題庫附答案解析
- 生產(chǎn)過程管理制度制度
- 電磁輻射環(huán)境下的職業(yè)健康防護(hù)
- 2026年及未來5年中國芋頭行業(yè)市場發(fā)展現(xiàn)狀及投資方向研究報告
- 中藥外洗治療化療導(dǎo)致外周神經(jīng)毒課件
- 2025-2026學(xué)年人教版(新教材)小學(xué)數(shù)學(xué)三年級下冊(全冊)教學(xué)設(shè)計(附目錄P208)
- 2025版中國慢性乙型肝炎防治指南
- 2026年及未來5年市場數(shù)據(jù)中國草酸行業(yè)發(fā)展前景預(yù)測及投資戰(zhàn)略數(shù)據(jù)分析研究報告
- 感染科結(jié)核病防治培訓(xùn)指南
- 2025年湖南生物機電職業(yè)技術(shù)學(xué)院單招職業(yè)適應(yīng)性考試模擬測試卷附答案
- 金屬水幕施工方案(3篇)
- 2025美國心臟協(xié)會心肺復(fù)蘇(CPR)與心血管急救(ECC)指南解讀
- 2024-2025學(xué)年浙江省金華市蘭溪市一年級(上)期末數(shù)學(xué)試卷
評論
0/150
提交評論